Quintiles 4th Quarter and Full Year 2015 Results and 2016 Guidance

  • 9.4% constant currency service revenue growth compared to the fourth quarter of 2014
  • $0.90 diluted adjusted EPS representing 26.8% growth compared to the fourth quarter of 2014, fourth quarter GAAP reported diluted EPS of $0.85
  • Net new business of $1.49 billion in the fourth quarter of 2015, representing a 1.32 book-to-bill ratio and increasing backlog to $12.04 billion as of December 31, 2015
  • $265 million of share repurchases during the fourth quarter of 2015
  • Full year 2016 service revenue guidance of 7.0% to 8.5% constant currency growth compared to full year 2015 and diluted adjusted EPS guidance of $3.70 to $3.85 per share, representing growth of 11.1% to 15.6% compared to full year 2015

DURHAM, N.C. Research Triangle Park, N.C.--()--Quintiles Transnational Holdings Inc. (“Quintiles” or the “Company”) (NYSE: Q) today reported its financial results for the quarter and year ended December 31, 2015.

For the three months ended December 31, 2015, the Company’s service revenues were $1.13 billion which represents growth of 6.1%, or $64.6 million, including an unfavorable foreign currency impact of $35.5 million compared to the same period last year. The Company’s growth in service revenues, excluding the impact of foreign currency fluctuations (“constant currency”), was 9.4% with 12.1% growth in the Product Development segment and 2.2% growth in the Integrated Healthcare Services segment.

Adjusted income from operations was $187.7 million in the fourth quarter of 2015, representing growth of 14.3% compared to the same period last year. The adjusted income from operations margin was 16.6%, representing 120 basis points of expansion compared to the same period last year and including 140 basis points of favorable currency fluctuations. Adjusted net income was $111.4 million in the fourth quarter of 2015, representing growth of 21.3% compared to the same period last year. Diluted adjusted earnings per share was $0.90 in the fourth quarter of 2015, representing growth of 26.8% compared to the same period last year.

Reported GAAP income from operations was $178.0 million, reported GAAP net income attributable to Quintiles was $104.6 million, and reported GAAP diluted earnings per share was $0.85 for the three months ended December 31, 2015. Reconciliations of the non-GAAP measures to the corresponding GAAP measures, including adjusted income from operations, adjusted net income, and diluted adjusted earnings per share, are attached to this press release.

For the year ended December 31, 2015, the Company’s service revenue growth was 3.9%, or $160.6 million, including an unfavorable foreign currency impact of $212.3 million compared to 2014. At constant currency, the Company’s service revenues grew 9.0% with 7.2% growth in the Product Development segment and 14.0% growth in the Integrated Healthcare Services segment. Adjusted income from operations for the year ended December 31, 2015 was $679.8 million, representing growth of 13.4% and 130 basis points of margin expansion compared to the same period last year, resulting from a constant currency improvement in Integrated Healthcare Services and the benefit of 130 basis points of favorable currency fluctuations across the Company. Adjusted net income was $418.9 million for the year ended December 31, 2015, representing growth of 18.5% compared to the same period last year. Diluted adjusted earnings per share was $3.33 for the year ended December 31, 2015, representing growth of 23.3% compared to 2014. Reported GAAP income from operations was $646.6 million, reported GAAP net income attributable to Quintiles was $387.2 million and reported GAAP diluted earnings per share was $3.08 for the year ended December 31, 2015.

Net new business of $1.49 billion was recorded for the fourth quarter, representing a book-to-bill ratio of 1.32. For the year ended December 31, 2015, net new business totaled $5.32 billion, representing a book-to-bill ratio of 1.23. The fourth quarter net new business contributed to an ending backlog of $12.04 billion at December 31, 2015.

“We are pleased to have achieved another year of consistent growth in 2015, having delivered 9.0% constant currency revenue growth, 23.3% diluted adjusted earnings per share growth, and a consolidated book-to-bill of 1.23,” said Quintiles Chief Executive Officer Tom Pike. “As expected, our Product Development segment delivered a strong fourth quarter, with 12.1% constant currency revenue growth and a 1.30 book-to-bill ratio. We believe we are well-positioned for the long-term with our $12.04 billion of backlog.”

The Product Development segment net new business totaled $1.10 billion in the quarter ended December 31, 2015, which translates to a book-to-bill ratio of 1.30. Product Development’s service revenues at constant currency grew 12.1%, or $93.7 million, during the fourth quarter of 2015 compared to the same period last year. At actual foreign exchange rates, Product Development service revenues were negatively impacted by $22.4 million of unfavorable foreign currency fluctuations, resulting in service revenue growth of 9.2% compared to the same period last year. The constant currency revenue growth resulted from Q2 Solutions and volume-related increases in core clinical services, clinical solutions provided on a functional resourcing basis, and clinical trial support services. Product Development’s income from operations margin was 23.7% for the fourth quarter, representing an improvement of 200 basis points compared to the same period last year, including a benefit of 190 basis points from favorable currency fluctuations.

The Integrated Healthcare Services segment net new business totaled $390 million in the quarter ended December 31, 2015, which translates to a book-to-bill ratio of 1.38. On a constant currency basis, Integrated Healthcare Services’ service revenues increased 2.2%, or $6.4 million, during the fourth quarter of 2015 compared to the same period last year. At actual foreign exchange rates, Integrated Healthcare Services’ service revenues declined 2.3% to $282.9 million, negatively impacted by $13.1 million from unfavorable foreign currency fluctuations. The constant currency revenue growth resulted from increases in real-world and late phase research services, offset by a decline in commercial services in North America due to cancellations, and a decline in Europe due primarily to the conclusion of an agreement to distribute pharmaceutical products in Italy in the fourth quarter of 2014. Integrated Healthcare Services’ income from operations margin was 8.2% for the fourth quarter, representing a decline of 20 basis points compared to the same period last year, due to lower margins in commercial services in North America and Japan, offset by higher margins in real world and late phase research.

General corporate and unallocated expenses were $35.4 million during the quarter ended December 31, 2015 compared to $28.2 million for the same period last year. Interest expense was $25.5 million during the quarter ended December 31, 2015 compared to $26.0 million for the same period last year.

The GAAP effective income tax rate was 32.1% for the fourth quarter of 2015 compared to 29.4% for the same period in 2014 and 29.5% for the full year ended December 31, 2015 compared to 29.9% for 2014.

Equity in earnings of unconsolidated affiliates was $0.3 million during the fourth quarter of 2015 compared to equity in losses of unconsolidated affiliates of $5.4 million for the same period last year.

Net income attributable to noncontrolling interests was $3.5 million during the quarter ended December 31, 2015, primarily due to the minority interest partner’s share in Q2 Solutions. There was no material net income attributable to noncontrolling interests in the same period last year.

The Company repurchased approximately 4.0 million shares of its common stock in the fourth quarter of 2015 for $265.0 million, and has approximately $144.5 million remaining under its repurchase authorization. The share repurchase program does not obligate the Company to acquire any particular amount of common stock, has no end date, and may be modified, suspended, or discontinued at any time.

Financial Guidance

For 2016, the Company expects to achieve service revenue constant currency growth between 7.0% and 8.5% compared to full year 2015, and diluted adjusted earnings per share of $3.70 to $3.85 per share, representing growth of 11.1% to 15.6% with diluted GAAP earnings per share between $3.52 and $3.70 per share, and an annual effective income tax rate estimated at approximately 29.0%. This financial guidance assumes January foreign currency exchange rates remain in effect for the remainder of the year and does not reflect the potential impact of any future equity repurchases.

Webcast & Conference Call Details

Quintiles will host a conference call at 8:00 a.m. EST today to discuss its fourth quarter and full year 2015 financial results. To participate, please dial +1 (855) 710-5091 or +1 (706) 902-0591 outside the United States approximately 15 minutes before the scheduled start of the call. The conference call will also be accessible live via webcast on the Investors section of the Quintiles website at www.quintiles.com/investors. An archived replay of the conference call will be available online at www.quintiles.com/investors after 1:00 p.m. EST today.

About Quintiles

Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s list of the “World’s Most Admired Companies.” To learn more, visit www.quintiles.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements reflect, among other things, the Company’s current expectations and anticipated results of operations, all of which are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, market trends or industry results to differ materially from those expressed or implied by such forward-looking statements. Therefore, any statements contained herein that are not statements of historical fact may be forward-looking statements and should be evaluated as such. Without limiting the foregoing, the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “should,” “guidance,” “targets,” “will” and the negative thereof and similar words and expressions are intended to identify forward-looking statements. Actual results may differ materially from the Company’s expectations due to a number of factors, including, but not limited to, that most of the Company’s contracts may be terminated on short notice, and that the Company may be unable to maintain large customer contracts or to enter into new contracts; the Company may under-price its contracts, overrun its cost estimates, or fail to receive approval for or experience delays in documenting change orders; the historical indications of the relationship of backlog to revenues may not be indicative of their future relationship; the Company may be unable to maintain information systems or effectively update them; customer or therapeutic concentration could harm the Company’s business; the Company’s business is subject to risks associated with international operations, including economic, political and other risks such as compliance with a myriad of laws and regulations, complications from conducting clinical trials in multiple countries simultaneously and changes in exchange rates; the Company may be unable to successfully identify, acquire and integrate businesses, services and technologies; the Company’s effective income tax rate may fluctuate, which may adversely affect our operations, earnings, and earnings per share; certain of the Company’s corporate governance documents could make an acquisition of the Company more difficult; and the Company has substantial indebtedness and may incur additional indebtedness in the future, which could adversely affect the Company’s financial condition. For a further discussion of the risks relating to the Company’s business, see the “Risk Factors” in Quintiles’ annual report on Form 10-K for the fiscal year ended December 31, 2014, filed with the SEC, as such factors may be amended or updated from time to time in Quintiles’ subsequent periodic filings with the SEC, which are accessible on the SEC's website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in Quintiles’ filings with the SEC. The Company assumes no obligation to update any such forward-looking statement after the date of this release, whether as a result of new information, future developments or otherwise.

Use of Non-GAAP Financial Measures

This press release includes adjusted EBITDA, adjusted income from operations, adjusted income from operations margin, adjusted net income and diluted adjusted earnings per share, each of which is a financial measure not prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). Management believes that these non-GAAP measures provide useful supplemental information to management and investors regarding the underlying performance of the Company’s business operations and are more indicative of core operating results as they exclude certain items whose fluctuations from period-to-period do not necessarily correspond to changes in the core operations of the business. These non-GAAP measures are performance measures only and are not measures of the Company’s cash flows or liquidity, nor are they alternatives for measures of financial performance prepared in accordance with GAAP and may be different from similarly titled non-GAAP measures used by other companies. Investors and potential investors are encouraged to review the reconciliations of the non-GAAP financial measures to their most directly comparable GAAP measures attached to this press release.

Internet Posting of Information: The Company routinely posts information that may be important to investors in the 'Investors' section of the Company’s website at www.quintiles.com. The Company encourages investors and potential investors to consult the Company’s website regularly for important information about the Company.

Click here to subscribe to Mobile Alerts for Quintiles.

QUINTILES TRANSNATIONAL HOLDINGS INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share data)
       
Three Months Ended Year Ended
December 31, December 31,
  2015     2014     2015     2014  
(unaudited)
Service revenues $ 1,128,599 $ 1,064,045 $ 4,326,419 $ 4,165,822
Reimbursed expenses   393,131     347,043     1,411,200     1,294,176  
Total revenues 1,521,730 1,411,088 5,737,619 5,459,998
Costs of revenue, service costs 696,856 674,819 2,725,586 2,684,106
Costs of revenue, reimbursed expenses 393,131 347,043 1,411,200 1,294,176
Selling, general and administrative 244,066 225,055 920,985 882,338
Restructuring costs 7,210 5,239 30,752 8,988
Impairment charges   2,484         2,484      
Income from operations 177,983 158,932 646,612 590,390
Interest income (847 ) (559 ) (4,317 ) (3,410 )
Interest expense 25,536 26,037 101,792 100,589
Loss on extinguishment of debt 7,780
Other (income) expense, net   (5,502 )   586     2,362     (8,978 )
Income before income taxes and equity in
earnings (losses) of unconsolidated affiliates 158,796 132,868 538,995 502,189
Income tax expense   51,009     39,007     158,989     150,056  
Income before equity in earnings (losses)
of unconsolidated affiliates 107,787 93,861 380,006 352,133
Equity in earnings (losses) of unconsolidated affiliates   300     (5,417 )   8,298     4,368  
Net income 108,087 88,444 388,304 356,501
Net income attributable to noncontrolling interests (3,517 ) (18 ) (1,099 ) (118 )
Net income attributable to Quintiles        
Transnational Holdings Inc. $ 104,570   $ 88,426   $ 387,205   $ 356,383  
Earnings per share attributable to common shareholders:
Basic $ 0.86 $ 0.70 $ 3.15 $ 2.78
Diluted $ 0.85 $ 0.69 $ 3.08 $ 2.72
Weighted average common shares outstanding:
Basic 120,966 125,638 123,038 127,994
Diluted 123,192 128,626 125,630 131,083
 
QUINTILES TRANSNATIONAL HOLDINGS INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except per share data)
 
December 31, December 31,
  2015     2014  
ASSETS
Current assets:
Cash and cash equivalents $ 977,151 $ 867,358
Restricted cash 2,478 2,882
Trade accounts receivable and unbilled services, net 1,165,749 975,255
Prepaid expenses 50,624 44,628
Deferred income taxes 100,978 118,515
Income taxes receivable 34,089 45,357
Other current assets and receivables   80,916     92,088  
Total current assets   2,411,985     2,146,083  
Property and equipment, net 188,393 190,297
Investments in debt, equity and other securities 32,911 34,503
Investments in and advances to unconsolidated affiliates 52,382 31,508
Goodwill 719,740 464,434
Other identifiable intangibles, net 368,106 280,243
Deferred income taxes 42,684 35,972
Deposits and other assets   110,115     112,913  
Total assets $ 3,926,316   $ 3,295,953  
LIABILITIES AND SHAREHOLDERS’ DEFICIT
Current liabilities:
Accounts payable $ 145,484 $ 108,743
Accrued expenses 760,757 733,644
Unearned income 584,646 543,305
Income taxes payable 35,173 55,694
Current portion of long-term debt and obligations
held under capital leases 48,513 826
Other current liabilities   19,603     29,688  
Total current liabilities 1,594,176 1,471,900
Long-term debt and obligations held under
capital leases, less current portion 2,419,293 2,282,612
Deferred income taxes 65,702 61,797
Other liabilities   182,826     183,656  
Total liabilities   4,261,997     3,999,965  
Commitments and contingencies
Shareholders’ deficit:
Common stock and additional paid-in capital,
300,000 shares authorized, $0.01 par value,
119,378 and 124,129 shares issued and outstanding at
December 31, 2015 and 2014, respectively 8,784 143,828
Accumulated deficit (461,635 ) (788,798 )
Accumulated other comprehensive loss   (111,366 )   (59,091 )
Deficit attributable to Quintiles Transnational
Holdings Inc.’s shareholders (564,217 ) (704,061 )
Noncontrolling interests   228,536     49  
Total shareholders’ deficit   (335,681 )   (704,012 )
Total liabilities and shareholders’ deficit $ 3,926,316   $ 3,295,953  
 
QUINTILES TRANSNATIONAL HOLDINGS INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
 
Year Ended
December 31,
  2015     2014  
Operating activities:
Net income $ 388,304 $ 356,501
Adjustments to reconcile net income to cash
provided by operating activities:
Depreciation and amortization 127,742 121,013
Amortization of debt issuance costs and discount 9,170 6,688
Amortization of accumulated other comprehensive
loss on terminated interest rate swaps 7,881
Share-based compensation 37,758 30,001
Gain on disposals of property and equipment, net (710 ) (975 )
Impairment of long-lived assets 2,484
Earnings from unconsolidated affiliates (8,265 ) (4,346 )
Loss (gain) on investments, net 1,012 (4,797 )
Provision for (benefit from) deferred income taxes 18,351 (6,168 )
Excess income tax benefits from share-based award activities (39,071 ) (20,303 )
Changes in operating assets and liabilities:
Accounts receivable and unbilled services (246,028 ) (78,630 )
Prepaid expenses and other assets 14,436 (40,832 )
Accounts payable and accrued expenses 104,350 45,804
Unearned income 53,847 19,943
Income taxes payable and other liabilities   4,430     7,855  
Net cash provided by operating activities 475,691 431,754
Investing activities:
Acquisition of property, equipment and software (78,391 ) (82,650 )
Acquisition of businesses, net of cash acquired 31,725 (92,201 )
Proceeds from disposition of property and equipment 2,491 1,611
Proceeds from sale of equity securities 5,861
Investments in and advances to unconsolidated
affiliates, net of payments received (12,350 ) (4,472 )
Termination of interest rate swaps (10,981 )
Other   551     (1,263 )
Net cash used in investing activities (66,955 ) (173,114 )
Financing activities:
Proceeds from issuance of debt 2,248,500 275,000
Payment of debt issuance costs (22,028 ) (1,455 )
Repayment of debt (2,056,780 ) (30,157 )
Proceeds from revolving credit facility 150,000
Repayment of revolving credit facility (150,000 )
Principal payments on capital lease obligations (4,296 ) (2,612 )
Contingent consideration paid (3,000 ) (3,000 )
Payment of common stock issuance costs (105 )
Stock issued under employee stock purchase and option plans 64,297 35,228
Repurchase of common stock (515,010 ) (415,131 )
Repurchase of stock options (8,415 )
Excess income tax benefits from share-based award activities   39,071     20,303  
Net cash used in financing activities (249,246 ) (130,344 )
Effect of foreign currency exchange rate changes on cash   (49,697 )   (39,081 )
Increase in cash and cash equivalents 109,793 89,215
Cash and cash equivalents at beginning of period   867,358     778,143  
Cash and cash equivalents at end of period $ 977,151   $ 867,358  
 
QUINTILES TRANSNATIONAL HOLDINGS INC. AND SUBSIDIARIES
CONSOLIDATED SEGMENT OPERATIONS
(in thousands)
 
Three Months Ended Year Ended
December 31, December 31,
  2015     2014     2015     2014  
(unaudited)
Service revenues
Product Development $ 845,659 $ 774,455 $ 3,191,630 $ 3,097,831
Integrated Healthcare Services   282,940     289,590     1,134,789     1,067,991  
Total service revenues 1,128,599 1,064,045 4,326,419 4,165,822
 
Costs of revenue, service costs
Product Development 476,004 446,445 1,828,734 1,820,937
Integrated Healthcare Services   220,852     228,374     896,852     863,169  
Total costs of revenue, service costs 696,856 674,819 2,725,586 2,684,106
 
Selling, general and administrative
Product Development 169,654 159,981 648,297 631,678
Integrated Healthcare Services 38,943 36,950 153,896 140,019
General corporate and unallocated   35,469     28,124     118,792     110,641  
Total selling, general and administrative 244,066 225,055 920,985 882,338
 
Income from operations
Product Development 200,001 168,029 714,599 645,216
Integrated Healthcare Services 23,145 24,266 84,041 64,803
General corporate and unallocated (35,469 ) (28,124 ) (118,792 ) (110,641 )
Restructuring costs (7,210 ) (5,239 ) (30,752 ) (8,988 )
Impairment charges   (2,484 )       (2,484 )    
Total income from operations $ 177,983   $ 158,932   $ 646,612   $ 590,390  
 
QUINTILES TRANSNATIONAL HOLDINGS INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP TO NON-GAAP MEASURES
(in thousands, except per share data)
(unaudited)
 
Three Months Ended Year Ended
December 31, December 31,
  2015     2014     2015     2014  

Adjusted EBITDA

Net income attributable to Quintiles Transnational Holdings Inc. $ 104,570 $ 88,426 $ 387,205 $ 356,383
Interest expense, net 24,689 25,478 97,475 97,179
Income tax expense 51,009 39,007 158,989 150,056
Depreciation and amortization 34,518 31,900 127,742 121,013
Restructuring costs 7,210 5,239 30,752 8,988
Impairment charges 2,484 2,484
Loss on extinguishment of debt 7,780
Adjustment to estimated contingent consideration   175         6,177     (8,839 )
Adjusted EBITDA $ 224,655   $ 190,050   $ 818,604   $ 724,780  
 

Adjusted Income from Operations

Income from operations $ 177,983 $ 158,932 $ 646,612 $ 590,390
Restructuring costs 7,210 5,239 30,752 8,988
Impairment charges   2,484         2,484      
Adjusted income from operations $ 187,677   $ 164,171   $ 679,848   $ 599,378  
 

Adjusted Net Income

Net income attributable to Quintiles Transnational Holdings Inc. $ 104,570 $ 88,426 $ 387,205 $ 356,383
Restructuring costs 7,210 5,239 30,752 8,988
Noncontrolling interests effect of non-GAAP adjustments (1) (89 ) (2,395 )
Impairment charges 2,484 2,484
Loss on extinguishment of debt 7,780
Adjustment to estimated contingent consideration 175 6,177 (8,839 )
Tax effect of adjustments (2)   (2,949 )   (1,816 )   (13,080 )   (3,114 )
Adjusted net income $ 111,401   $ 91,849   $ 418,923   $ 353,418  
 
Diluted weighted average common shares outstanding 123,192 128,626 125,630 131,083
Diluted adjusted earnings per share $ 0.90 $ 0.71 $ 3.33 $ 2.70
 
(1) Reflects the portion of Q2 Solutions’ after-tax non-GAAP adjustments attributable to the minority interest partner.
 
(2) The tax effect of adjustments was based on the income tax rate of the respective transactions, which was 38.5%, with the exception of (i) restructuring costs which were tax effected at 27.6% and 34.7% during the three months ended December 31, 2015 and 2014, respectively, and 29.7% and 34.6% during the year ended December 31, 2015 and 2014, respectively and (ii) contingent consideration which is not tax effected as it represents a permanent difference between book and tax income.
 
QUINTILES TRANSNATIONAL HOLDINGS INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP TO NON-GAAP MEASURES (Continued)
(in millions, except per share data)
(unaudited)
 
Reconciliation of GAAP to Non-GAAP Full Year 2016 Guidance
Diluted Adjusted
Adjusted Net Income Earnings Per Share
Low High Low High
Net income attributable to Quintiles and diluted earnings per share $ 432 $ 454 $ 3.52 $ 3.70
Restructuring costs, net of tax and noncontrolling interests (1)   22     19     0.18     0.15  
Adjusted net income and diluted adjusted earnings per share $ 454   $ 473   $ 3.70   $ 3.85  
 

(1) Restructuring costs are adjusted for the portion attributable to the minority interest partner in Q2 Solutions and are tax effected at

approximately 30.0%.

 
Note: Totals may not sum due to rounding.

Contacts

Quintiles
Phil Bridges, Media Relations
Office: 919-998-1653
Mobile: 919-457-6347
phil.bridges@quintiles.com
or
Todd Kasper, Investor Relations
919-998-2590
InvestorRelations@quintiles.com

Release Summary

Quintiles Transnational Holdings Inc. (NYSE: Q) today reported its financial results for the quarter ended December 31, 2015.

Contacts

Quintiles
Phil Bridges, Media Relations
Office: 919-998-1653
Mobile: 919-457-6347
phil.bridges@quintiles.com
or
Todd Kasper, Investor Relations
919-998-2590
InvestorRelations@quintiles.com